Results 151 to 160 of about 19,745 (243)

Extracellular vesicles in multiple myeloma: pathogenesis and therapeutic application

The FEBS Journal, EarlyView.
Multiple myeloma is characterised by the clonal proliferation of plasma cells in the bone marrow. Extracellular vesicles (EVs) are a key component of cell‐to‐cell communication within the bone marrow microenvironment, promoting tumour growth, bone remodelling, immune modulation, angiogenesis and therapeutic resistance.
Chloe Wylie, Rebecca Rowan, Dessi Malinova, Lisa Crawford   +3 more
wiley   +1 more source

Comparison of enriched charge variants from different anti-CD3 bispecific antibodies reveals differential susceptibility of each bispecific arm to post-translational modification. [PDF]

Protein Sci
Nguyen JB, Liu S, Howie DA, Oberholtzer ZR, Ong ET, Rao R, Prinston JE, Dikiy I, Wu J, Wu Z, Zhao Y, Li M, Molden R, Molina G, Provoncha K, Sandu C, Qiu H, Li N, Matousek W, Rosconi MP, Pyles EA.   +20 more
europepmc   +1 more source

Haemophilia Prophylaxis in the Age of Innovation: Exploring Opportunities for Personalized Treatment

Haemophilia, EarlyView.
ABSTRACT Introduction Recent advancements in haemophilia treatment have introduced a range of innovative therapies, including activated FVIII mimetics, ultra‐extended half‐life recombinant FVIII, rebalancing agents and gene therapy. These developments have transformed treatment options and expanded prophylaxis strategies.
Yesim Dargaud, Fabienne Volot, Stephanie Desage, Claire Pouplard, Valerie Chamouard, Anne Lienhart   +5 more
wiley   +1 more source

Chimeric antigen receptor T-cell therapy remains effective after exposure to bispecific antibodies. Comment to "Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma". [PDF]

Haematologica
Crochet G, Houot R.
europepmc   +1 more source

Temporal trends in relative survival of diffuse large B‐cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies

British Journal of Haematology, EarlyView.
Sara Harrysson, Sandra Eloranta, Stefanie Antonilli, Mikkel Runason Simonsen, Kristina Sonnevi, Peter Brown, Bjorn E. Wahlin, Per‐Ola Andersson, Judit M. Jørgensen, Mats Jerkeman, Christian B. Poulsen, Gunilla Enblad, Tarec C. El‐Galaly, Karin E. Smedby   +13 more
wiley   +1 more source

Bispecific antibodies in immunotherapy for acute leukemia: latest updates from the 66th annual meeting of the American society of hematology, 2024. [PDF]

Front Oncol
Cao W, Ma S, Han L, Xing H, Li Y, Jiang Z, Guo X, Yu J.   +7 more
europepmc   +1 more source

European Principles of Nursing Care for Persons With Inherited Bleeding Disorders

Haemophilia, EarlyView.
ABSTRACT Introduction A nurse is one of the core members of the multidisciplinary haemophilia team. However, what people with inherited bleeding disorders (PwBD) can expect from them has not yet been formally defined. Aim This project, initiated by the EAHAD Nurses Committee, aimed to establish Principles of Nursing Care (PoNC) for PwBD to promote high‐
Nanda Uitslager, Mary Kavanagh, Maj Birkedal, Linda Myrin‐Westesson   +3 more
wiley   +1 more source

Design of orthogonal constant domain interfaces to aid proper heavy/light chain pairing of bispecific antibodies. [PDF]

MAbs
Barlow KA, Battles MB, Brown ME, Canfield K, Lu X, Lynaugh H, Morrill M, Rappazzo CG, Reyes SP, Sandberg C, Sharkey B, Strong C, Zhao J, Sivasubramanian A.   +13 more
europepmc   +1 more source

A new era in myeloma: the advent of chimeric antigen receptor‐T (CAR‐T) cells and bispecific antibodies

Internal Medicine Journal, EarlyView.
Abstract T‐cell re‐directional therapies, including chimeric antigen receptor (CAR)‐T cell and bispecific antibodies (BsA), have transformed the treatment landscape to benefit patients with multiple myeloma. A number of these novel therapies has been approved internationally, with CAR‐T therapy recently approved in Australia.
P. Joy Ho, Eric W. Li
wiley   +1 more source

Design and Characterization of Bispecific and Trispecific Antibodies Targeting SARS-CoV-2. [PDF]

Vaccines (Basel)
Wang J, Qian Q, Jiang Y, Liang Z, Peng Y, Zhao W, Yang Y, Shen C.   +7 more
europepmc   +1 more source